Fuchs Charles S.
Transaction: 08/10/2026
OTHER
Change
0
Price
Not reported
Filing
08/12/2026
Type
OTHER
Erasca, Inc.
ERAS • Biotechnology
$16.19
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$5.04B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.14Healthy liquidity · 10.04Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:47 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$16.19
Change0.00%
Shares Out311.34M
Market Cap$5.04B
Enterprise Value$4.82B
52W Range1.33 - 24.28
Beta0.67
P/E-17.55
P/B13.93
P/FCF-51.39
EV/EBITDA-32.87
EV/FCF-49.11
Price$16.19
Change0.00%
Shares Out311.34M
Market Cap$5.04B
Enterprise Value$4.82B
52W Range1.33 - 24.28
Beta0.67
P/E-17.55
P/B13.93
P/FCF-51.39
EV/EBITDA-32.87
EV/FCF-49.11
Earnings Yield-5.70%
FCF Yield-1.95%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.14
Current Ratio10.04
Quick Ratio10.04
Target$22.50
Target Upside38.97%
Target Median$21.50
Target Range16.00 - 30.00
Volume2.60M
Avg Volume6.22M
EPS Surprise0.01
Investment DNA
How strong this company looks for long-term investors
44
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
76/100
Why this score▼
Manageable debt level · 0.14Healthy liquidity · 10.04Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 11 analyst votes · 2026-09-05
91/100
Bullish
Bullish
9
Hold
2
Bearish
0
Price Target
2026-08-14
Low
$16.00
Mean
$22.50
Median
$21.50
High
$30.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Fuchs Charles S.
Transaction: 08/10/2026
BUY
Change
+1,300,000
Price
$18.12
Filing
08/12/2026
Type
BUY
Bristol James Arthur
Transaction: 06/26/2026
BUY
Change
+29,888
Price
$16.01
Filing
06/29/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Fuchs Charles S. | OTHER | 0 | Not reported | 08/10/2026 | 08/12/2026 |
| Fuchs Charles S. | BUY | +1,300,000 | $18.12 | 08/10/2026 | 08/12/2026 |
| Bristol James Arthur | BUY | +29,888 | $16.01 | 06/26/2026 | 06/29/2026 |
| Hambleton Julie | BUY | +29,888 | $16.01 | 06/26/2026 | 06/29/2026 |
| Casdin Alexander W. | BUY | +29,888 | $16.01 | 06/26/2026 | 06/29/2026 |
| Multani Pratik S | BUY | +29,888 | $16.01 | 06/26/2026 | 06/29/2026 |
| LIU JEAN I | BUY | +29,888 | $16.01 | 06/26/2026 | 06/29/2026 |
| Start Valerie Denise Harding | BUY | +29,888 | $16.01 | 06/26/2026 | 06/29/2026 |
| Garner Ebun | SELL | -80,000 | $16.40 | 04/01/2026 | 04/03/2026 |
| Garner Ebun | SELL | -80,000 | $1.70 | 04/01/2026 | 04/03/2026 |
| Morris Shannon | SELL | -20,000 | $15.04 | 03/04/2026 | 03/06/2026 |
| Morris Shannon | SELL | -20,000 | $1.70 | 03/04/2025 | 03/06/2026 |
| Garner Ebun | BUY | +560,000 | $10.31 | 01/29/2026 | 01/30/2026 |
| Varney Michael David | BUY | +96,000 | $10.31 | 01/29/2026 | 01/30/2026 |
| Morris Shannon | BUY | +625,000 | $10.31 | 01/29/2026 | 01/30/2026 |
| Chacko David M. | BUY | +640,000 | $10.31 | 01/29/2026 | 01/30/2026 |
| Lim Jonathan E | BUY | +2,000,000 | $10.31 | 01/29/2026 | 01/30/2026 |
| Chacko David M. | BUY | +17,793 | $1.19 | 12/15/2025 | 01/30/2026 |
| Garner Ebun | SELL | -120,000 | $5.59 | 01/07/2026 | 01/08/2026 |
| Garner Ebun | BUY | +3,902 | $1.19 | 12/15/2025 | 01/08/2026 |